These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8540760)

  • 1. Pharmacokinetics of zidovudine and didanosine during combination therapy.
    Morse GD; Shelton MJ; Ho M; Bartos L; DeRemer M; Ragni M
    Antiviral Res; 1995 Aug; 27(4):419-24. PubMed ID: 8540760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection.
    Mueller BU; Pizzo PA; Farley M; Husson RN; Goldsmith J; Kovacs A; Woods L; Ono J; Church JA; Brouwers P
    J Pediatr; 1994 Jul; 125(1):142-6. PubMed ID: 8021765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
    Collier AC; Coombs RW; Fischl MA; Skolnik PR; Northfelt D; Boutin P; Hooper CJ; Kaplan LD; Volberding PA; Davis LG; Henrard DR; Weller S; Corey L
    Ann Intern Med; 1993 Oct; 119(8):786-93. PubMed ID: 8379600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
    Perry CM; Balfour JA
    Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients.
    Sahai J; Gallicano K; Garber G; Pakuts A; Cameron W
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):54-60. PubMed ID: 7648285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine.
    Shelton MJ; Adams JM; Hewitt RG; Steinwandel C; DeRemer M; Cousins S; Morse GD
    Pharmacotherapy; 1997; 17(3):438-44. PubMed ID: 9165548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
    Gibb D; Barry M; Ormesher S; Nokes L; Seefried M; Giaquinto C; Back D
    Br J Clin Pharmacol; 1995 May; 39(5):527-30. PubMed ID: 7669489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
    Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives on antiretroviral therapy.
    Fletcher CV
    Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
    Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
    Conway B; Wainberg MA; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange JM; Montaner JS
    AIDS; 2001 Jul; 15(10):1269-74. PubMed ID: 11426071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination anti-HIV therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine/didanosine prodrug.
    Jin Y; Xin R; Tong L; Du L; Li M
    Mol Pharm; 2011 Jun; 8(3):867-76. PubMed ID: 21553876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.